XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.3
SEGMENT AND ENTERPRISE-WIDE INFORMATION
 6 Months Ended
Sep. 28, 2024
Segment Reporting [Abstract]  
SEGMENT AND ENTERPRISE-WIDE INFORMATION
16. SEGMENT AND ENTERPRISE-WIDE INFORMATION

The Company determines its reportable segments by first identifying its operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. The Company’s reporting structure aligns with its operating structure of three global business units and the information that is regularly reviewed by the Company’s chief operating decision maker.

The Company’s reportable and operating segments are as follows:
•Plasma
•Blood Center
•Hospital

Management measures and evaluates the operating segments based on operating income. Management excludes certain corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. Management measures and evaluates the Company’s net revenues and operating income using internally derived standard currency exchange rates that remain constant from year to year; therefore, segment information is presented on this basis.

Selected information by reportable segment is presented below:
Three Months EndedSix Months Ended
(In thousands)September 28,
2024		September 30,
2023		September 28,
2024		September 30,
2023
Net revenues(1)
Plasma$138,565 $142,643 $274,607 $282,134 
Blood Center68,804 70,470 135,643 139,639 
Hospital138,384 105,950 272,790 208,378 
Net revenues in constant currency345,753 319,063 683,040 630,151 
Effect of exchange rates(242)(880)(1,357)(636)
Net revenues$345,511 $318,183 $681,683 $629,515 
(1) Beginning in fiscal 2025, the Company integrated service revenue within its three business units. Prior periods were conformed to current presentation.
Three Months EndedSix Months Ended
(In thousands)September 28,
2024		September 30,
2023		September 28,
2024		September 30,
2023
Segment operating income
Plasma$69,728 $78,042 $135,565 $153,740 
Blood Center27,167 27,307 49,789 53,590 
Hospital59,705 41,834 113,596 82,777 
Segment operating income156,600 147,183 298,950 290,107 
Corporate expenses (1)
(74,407)(75,750)(144,387)(151,059)
Effect of exchange rates1,312 (3,091)(37)(478)
Amortization of acquired intangible assets(12,264)(7,222)(24,735)(14,695)
Amortization of fair value inventory step-up(3,739)— (8,978)— 
Integration and transaction costs(882)(1,784)(13,205)(2,899)
Restructuring costs(4,792)(86)(9,414)(75)
Restructuring related costs(1,571)(1,947)(4,089)(4,151)
Digital transformation costs(4,858)(3,592)(11,203)(7,297)
PCS2 related charges— (552)— (411)
MDR and IVDR costs(991)(1,988)(2,117)(3,154)
Litigation-related charges(320)(5,449)(1,075)(6,507)
Impairment of intangible assets(2,391)(10,419)(2,391)(10,419)
Gain on sale of property, plant and equipment— — 14,134 — 
Operating income$51,697 $35,303 $91,453 $88,962 
(1) Reflects shared service expenses including quality and regulatory, customer and field service, research and development, manufacturing and supply chain, as well as other corporate support functions.

Net revenues by business unit are as follows:
  Three Months EndedSix Months Ended
(In thousands)September 28,
2024		September 30,
2023		September 28,
2024		September 30,
2023
 Plasma$138,561 $142,794 $274,471 $282,415 
Apheresis54,332 54,973 103,426 104,139 
Whole Blood14,196 14,683 31,347 34,723 
 Blood Center68,528 69,656 134,773 138,862 
Interventional Technologies(1)
61,923 38,541 124,967 76,161 
Blood Management Technologies(2)
76,499 67,192 147,472 132,077 
 Hospital138,422 105,733 272,439 208,238 
Net revenues(3)
$345,511 $318,183 $681,683 $629,515 
(1) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines of the Hospital business unit.
(2) Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the Hospital business unit.
(3) Beginning in fiscal 2025, the Company integrated service revenue within its three business units. Prior periods were conformed to current presentation.
Net revenues generated in the Company’s principle operating regions on a reported basis are as follows:
Three Months EndedSix Months Ended
(In thousands)September 28,
2024		September 30,
2023		September 28,
2024		September 30,
2023
United States$256,061 $236,345 $504,963 $473,418 
Japan16,424 15,011 30,129 26,784 
Europe41,991 38,666 89,216 78,053 
Rest of Asia25,768 27,735 45,551 49,775 
Other5,267 426 11,824 1,485 
Net revenues$345,511 $318,183 $681,683 $629,515